We chose to study the role of RGS16 in pancreatic cancer cell migration due in part to its down-regulation in patients with metastasized pancreatic cancer and the high rate of p53 mutations (50-70%) and p16 deletions (85%) affecting both the p53 and pRb pathways in this disease [6, 7, 26]. This evidence concerns the gene TP53 and pancreatic neoplasm.